Cosentyx's Impact on Inactivated Vaccine Response
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis and other conditions, has minimal impact on immune responses to inactivated vaccines. Clinical studies show patients on Cosentyx mount antibody responses comparable to placebo groups after inactivated vaccines like the seasonal influenza vaccine.[1][2]
In the COREIMMUNE trial, adults with psoriasis received Cosentyx (300 mg) or placebo, followed by a single dose of inactivated trivalent influenza vaccine. Seroprotection rates (≥40 hemagglutination inhibition titer) for influenza strains A/H1N1, A/H3N2, and B were 75-95% in both groups at day 28, with geometric mean titers rising similarly. No significant differences emerged.[1]
Live vs. Inactivated Vaccines with Cosentyx
Cosentyx does not broadly suppress adaptive immunity like TNF inhibitors, preserving responses to non-live vaccines. Product labeling recommends inactivated vaccines anytime, even during treatment, but cautions against live vaccines due to infection risks.[2] Real-world data aligns, with no reduced efficacy for tetanus, pneumococcal, or COVID-19 inactivated boosters reported in secukinumab users.[3]
Clinical Trial Evidence Breakdown
- Influenza vaccine trial (n=246): Seroconversion rates matched placebo (e.g., 52-68% vs. 50-70% across strains). Cell-mediated responses (T-cell proliferation) were also unaffected.[1]
- Pneumococcal vaccine study: Similar antibody titers post-vaccination in Cosentyx patients vs. controls.[4]
No long-term waning of response noted up to 6 months post-vaccination.
Patient and Timing Considerations
Vaccinate before starting Cosentyx if possible, though responses hold during steady-state dosing (every 4 weeks after loading). Monitor high-risk patients (e.g., elderly, comorbidities) for suboptimal responses, as seen rarely with biologics. No interactions with adjuvants in inactivated formulations.[2]
Comparison to Other Biologics
Unlike IL-17/IL-23 inhibitors like Taltz (ixekizumab) or Skyrizi (risankizumab), which show preserved inactivated vaccine responses, TNF blockers (e.g., Humira) more often blunt them by 20-50%.[5] JAK inhibitors like Xeljanz pose higher live vaccine risks but match Cosentyx on inactivated ones.
[1] PubMed: COREIMMUNE trial (Bachelez et al., 2016)
[2] Cosentyx Prescribing Information (Novartis)
[3] JAMA Dermatology: COVID vaccine response in IL-17 inhibitors (Furer et al., 2022)
[4] Annals of Rheumatic Diseases: Pneumococcal response (Kivitz et al., 2017)
[5] Rheumatology: Biologic vaccine comparisons (Furer et al., 2021)